Literature DB >> 8980259

Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease.

S J Marcus1, T R Kinney, W H Schultz, E E O'Branski, R E Ware.   

Abstract

Variation in the level of fetal hemoglobin (HbF) accounts for much of the clinical heterogeneity observed in patients with sickle cell disease (SCD). The HbF level has emerged as an important prognostic factor in both sickle cell pain and mortality, and a % HbF of 10-20% has been suggested as a threshold level for diminished clinical severity. The number of erythrocytes that contain HbF (termed F cells) may also be critically important, as F cells resist intravascular sickling and have preferential in vivo survival. Since F cells can be enumerated with high accuracy using flow cytometry methods, we prospectively studied a cohort of 242 children with SCD. Children with HbS and hereditary persistence of fetal hemoglobin (S/HPFH) had essentially 100% F cells. In contrast, children with homozygous sickle cell anemia (HbSS), HbS/beta0 thalassemia, or HbS/beta+ thalassemia had significantly lower mean % F cell values (55.9, 61.6, and 51.3%, respectively; P < 0.001), and children with HbSC had even fewer F cells (27.0%; P < 0.001). There was a highly significant correlation between the % F cells and the log (% HbF), which was observed for the total population of children (r = 0.95, P < 0.001), as well as for each of the individual subgroups of children with HbSS (r = 0.94, P < 0.001), HbSC (r = 0.89, P < 0.001), or HbS/beta0 thalassemia and HbS/beta+ thalassemia (r = 0.95, P <0.001). This logarithmic correlation between % F cells and % HbF has not been previously described and has important implications for the pharmacologic manipulation of HbF in patients with SCD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8980259     DOI: 10.1002/(sici)1096-8652(199701)54:1<40::aid-ajh6>3.0.co;2-4

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  16 in total

1.  Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic β-type globin promoters in differentiated adult erythroid cells.

Authors:  Shuaiying Cui; Katarzyna E Kolodziej; Naoshi Obara; Alexandra Amaral-Psarris; Jeroen Demmers; Lihong Shi; James Douglas Engel; Frank Grosveld; John Strouboulis; Osamu Tanabe
Journal:  Mol Cell Biol       Date:  2011-06-13       Impact factor: 4.272

2.  A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.

Authors:  Jeremie H Estepp; Matthew P Smeltzer; Guolian Kang; Chen Li; Winfred C Wang; Christina Abrams; Banu Aygun; Russell E Ware; Kerri Nottage; Jane S Hankins
Journal:  Am J Hematol       Date:  2017-09-28       Impact factor: 10.047

3.  Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.

Authors:  Jane S Hankins; Russell E Ware; Zora R Rogers; Lynn W Wynn; Peter A Lane; J Paul Scott; Winfred C Wang
Journal:  Blood       Date:  2005-10-01       Impact factor: 22.113

4.  Expression patterns of fetal hemoglobin in sickle cell erythrocytes are both patient- and treatment-specific during childhood.

Authors:  Emily Riehm Meier; Colleen Byrnes; Maxine Weissman; Pierre Noel; Naomi L C Luban; Jeffery L Miller
Journal:  Pediatr Blood Cancer       Date:  2011-01       Impact factor: 3.167

5.  Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.

Authors:  R Borba; C S P Lima; H Z W Grotto
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

6.  PGC-1 coactivator activity is required for murine erythropoiesis.

Authors:  Shuaiying Cui; Osamu Tanabe; Kim-Chew Lim; H Eric Xu; X Edward Zhou; Jiandie D Lin; Lihong Shi; Lindsay Schmidt; Andrew Campbell; Ritsuko Shimizu; Masayuki Yamamoto; James Douglas Engel
Journal:  Mol Cell Biol       Date:  2014-03-24       Impact factor: 4.272

Review 7.  Heterogeneity of fetal hemoglobin production in adult red blood cells.

Authors:  Eugene Khandros; Gerd A Blobel
Journal:  Curr Opin Hematol       Date:  2021-05-01       Impact factor: 3.284

8.  Foetal haemoglobin, erythrocytes containing foetal haemoglobin, and hematological features in congolese patients with sickle cell anaemia.

Authors:  L Tshilolo; V Summa; C Gregorj; C Kinsiama; J A Bazeboso; G Avvisati; D Labie
Journal:  Anemia       Date:  2012-07-05

9.  An erythroid-to-myeloid cell fate conversion is elicited by LSD1 inactivation.

Authors:  Lei Yu; Greggory Myers; Chia-Jui Ku; Emily Schneider; Yu Wang; Sharon A Singh; Natee Jearawiriyapaisarn; Andrew White; Takashi Moriguchi; Rami Khoriaty; Masayuki Yamamoto; Michael G Rosenfeld; Julien Pedron; John H Bushweller; Kim-Chew Lim; James Douglas Engel
Journal:  Blood       Date:  2021-11-04       Impact factor: 22.113

10.  Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.

Authors:  Charles T Quinn; Omar Niss; Min Dong; Amanda Pfeiffer; Jennifer Korpik; Mary Reynaud; Holly Bonar; Theodosia A Kalfa; Luke R Smart; Punam Malik; Russell E Ware; Alexander A Vinks; Patrick T McGann
Journal:  Br J Haematol       Date:  2021-07-05       Impact factor: 8.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.